Given that Runx2 expression is elevated in metastatic bone lesions of breast cancer patients but absent in corresponding primary tumors,31 employment of a Runx2-activatable therapy should result in maximal iNOS transgene expression in the most aggressive tumor sites and spare normal tissue.33 This evidence concerns the gene RUNX2 and breast carcinoma.